Methoxyketamine
|
Names
|
IUPAC name
2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone
|
Identifiers
|
|
|
|
|
ChemSpider
|
|
|
|
UNII
|
|
|
|
InChI=1S/C14H19NO2/c1-15-14(10-6-5-9-13(14)16)11-7-3-4-8-12(11)17-2/h3-4,7-8,15H,5-6,9-10H2,1-2H3 Key: OYAUVHORXFUVAJ-UHFFFAOYSA-N InChI=1/C14H19NO2/c1-15-14(10-6-5-9-13(14)16)11-7-3-4-8-12(11)17-2/h3-4,7-8,15H,5-6,9-10H2,1-2H3 Key: OYAUVHORXFUVAJ-UHFFFAOYAM
|
|
Properties
|
|
C14H19NO2
|
Molar mass
|
233.311 g·mol−1
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
|
Methoxyketamine or 2-MeO-2-deschloroketamine is a designer drug of the arylcyclohexylamine class first reported in 1963.[1] It is an analog of ketamine in which the chlorine atom has been replaced with a methoxy group. Its synthesis by rearrangement of an amino ketone has been reported.[2] As an arylcyclohexylamine, methoxyketamine most likely functions as an NMDA receptor antagonist. It produces sedative, hallucinogenic, and (at high doses) anesthetic effects, but with a lower potency than ketamine itself.
See also
References
- ^ BE 634208, Stevens, Calvin L., "Amino ketones", published 1963
- ^ Stevens, Calvin L.; Thuillier, Andre; Taylor, K. Grant; Daniher, Francis A.; Dickerson, James P.; Hanson, Harry T.; Nielsen, Norman A.; Tikotkar, N. A.; Weier, Richard M. (1966). "Amino Ketone Rearrangements. VII.1 Synthesis of 2-Methylamino-2-Substituted Phenylcyclohexanones". The Journal of Organic Chemistry. 31 (8): 2601. doi:10.1021/jo01346a034.
|
---|
Psychedelics (5-HT2AR agonists) |
- Tryptamines (e.g., DMT, psilocin, psilocybin, bufotenin, 5-MeO-DMT, AMT)
- Phenethylamines (e.g., mescaline, 2C-B, DOM, MDA, TMA, 2C-B-FLY, 25I-NBOMe)
- Lysergamides (e.g., LSD, ergine, isoergine)
- Others (e.g., quipazine, efavirenz)
- For a full list of serotonergic psychedelics, see the navbox here instead.
|
---|
Dissociatives (NMDAR antagonists) | |
---|
Deliriants (mAChR antagonists) | |
---|
Cannabinoids (CB1R agonists) | |
---|
κOR agonists | |
---|
GABAAR agonists | |
---|
Inhalants (mixed MoATooltip mechanism of action) | |
---|
Others |
- Aminochromes (e.g., adrenochrome, adrenolutin)
- Carbogen
- Certain GABAA receptor positive allosteric modulators (nonbenzodiazepines/Z-drugs) (e.g., eszopiclone, zaleplon, zolpidem, zopiclone)
- CI-966
- Glaucine
- Hallucinogenic bolete mushrooms (e.g., Lanmaoa asiatica)
- Harmala alkaloids/β-carbolines (e.g., harmaline, 6-methoxyharmalan)
- Iboga alkaloids/azepinoindoles (e.g., ibogaine)
- Isoaminile
- Noscapine
- Oneirogens (e.g., Calea zacatechichi, galantamine, nicotine, Silene capensis)
- Prenoxdiazine
- Pukateine
|
---|
- See also: Psychedelics
- Entactogens
- Stimulants
- Depressants
|
|
---|
|
---|
AMPARTooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor | |
---|
KARTooltip Kainate receptor | |
---|
NMDARTooltip N-Methyl-D-aspartate receptor | |
---|
- See also: Receptor/signaling modulators
- Metabotropic glutamate receptor modulators
- Glutamate metabolism/transport modulators
|
|
---|
Group I | mGluR1Tooltip Metabotropic glutamate receptor 1 | |
---|
mGluR5Tooltip Metabotropic glutamate receptor 5 | |
---|
|
---|
Group II | mGluR2Tooltip Metabotropic glutamate receptor 2 | |
---|
mGluR3Tooltip Metabotropic glutamate receptor 3 | |
---|
|
---|
Group III | mGluR4Tooltip Metabotropic glutamate receptor 4 |
- Antagonists: CPPG
- MAP4
- MPPG
- MSOP
- MTPG
- UBP-1112
|
---|
mGluR6Tooltip Metabotropic glutamate receptor 6 |
- Antagonists: CPPG
- MAP4
- MPPG
- MSOP
- MTPG
- UBP-1112
|
---|
mGluR7Tooltip Metabotropic glutamate receptor 7 |
- Antagonists: CPPG
- MAP4
- MMPIP
- MPPG
- MSOP
- MTPG
- UBP-1112
- XAP044; Negative allosteric modulators: ADX71743
|
---|
mGluR8Tooltip Metabotropic glutamate receptor 8 |
- Antagonists: CPPG
- MAP4
- MPPG
- MSOP
- MTPG
- UBP-1112
|
---|
|
---|
See also: Receptor/signaling modulators • Ionotropic glutamate receptor modulators • Glutamate metabolism/transport modulators |
|